Pharmacological Management of Type 2 Diabetes Mellitus: An Update

Author(s): Samer El-Kaissi, Suphia Sherbeeni

Journal Name: Current Diabetes Reviews

Volume 7 , Issue 6 , 2011

Become EABM
Become Reviewer


While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagon- like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.

Keywords: Type 2 diabetes mellitus, Insulin, Thiazolidinediones, Sulphonylurea, Metformin, Glucagon-like peptide-1, Dipeptidyl peptidase-IV inhibitor, Bromocriptine, Alpha glucosidase inhibitor, Colesevelam

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [392 - 405]
Pages: 14
DOI: 10.2174/157339911797579160
Price: $65

Article Metrics

PDF: 31